Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Venlafaxine free base (Wy-45030; Wy45030; Effexor, Lanvexin, Viepax and Trevilor) is a marketed and arylalkanolamine-based antidepressant acting as an serotonin-norepinephrine reuptake inhibitor (SNRI). It is used to treat various disorders including major depressive disorder (MDD), panic disorder and social phobia, generalised anxiety disorder (GAD).
ln Vitro |
The binding of the serotonin transporter radioligand [3H]-paroxetine to cell membranes transfected with the human 5-HT transporter is dose-dependently inhibited by venlafaxine (Wy 45030), with a Ki of 2.48 μM. With a Ki of 82 nM, venlafaxine prevents the NE transporter ligand [3H]-nisoxetine from attaching to the membrane of a transfected human NE transporter [1]. With ED50 values of 2 and 54 mg/kg, respectively, venlafaxine inhibits the binding to the rat 5-HT transporter and the NE transporter in vitro[1].
|
---|---|
ln Vivo |
In the rat hypothalamus, venlafaxine (Wy 45030; 10-100 mg/kg; IP) dose-dependently prevents the 6-OHDA-induced reduction of norepinephrine levels [1].
|
Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, body weight 180-230 grams [1]
Doses: 10, 30, 100 mg/kg Route of Administration: IP; para-chloramphetamine hydrochloride (p-CA; 10 mg/kg; intraperitoneal (ip) injection ) Results one hour before: dose-dependently blocked 6-OHDA-induced depletion of norepinephrine levels in the rat hypothalamus (intracerebroventricular; 50 μg/rat; one hour later)), ED50 values were 12 and 94 mg/kg. |
References |
[1]. Bymaster FP, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001 Dec;25(6):871-80.
[2]. Goeringer KE, et al. Postmortem tissue concentrations of venlafaxine. Forensic Sci Int. 2001 Sep 15;121(1-2):70-5. |
Molecular Formula |
C17H27NO2
|
---|---|
Molecular Weight |
277.40178
|
CAS # |
93413-69-5
|
Related CAS # |
Venlafaxine hydrochloride;99300-78-4;Venlafaxine-d6;1020720-02-8;Venlafaxine-d6-1;940297-06-3
|
SMILES |
OC1(C(C2=CC=C(OC)C=C2)CN(C)C)CCCCC1
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.6049 mL | 18.0245 mL | 36.0490 mL | |
5 mM | 0.7210 mL | 3.6049 mL | 7.2098 mL | |
10 mM | 0.3605 mL | 1.8025 mL | 3.6049 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.